Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA.
Govers TM, et al. Among authors: hessels d.
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20.
Prostate Cancer Prostatic Dis. 2019.
PMID: 30127462